In Brief: Zer Hitech, Ltd.
This article was originally published in The Gray Sheet
Executive Summary
Zer Hitech, Ltd.: Jerusalem-based company gives Calcol the go-ahead in Dec. 9 letter of intent to form within six months a new company that would have rights to manufacture and distribute Zer Hitech's portfolio of in vitro diagnostic tests, which are either marketed outside the U.S. or are under development. Calcol would be responsible for FDA approval of the IVD kits, which test for pregnancy, ovulation, menopause and HIV I/II. Test kits for hepatitis B and drugs of abuse are still under development. If Zer Hitech forms partnerships with other firms for its pregnancy, ovulation and menopause tests, Calcol would lose rights to those products...
You may also be interested in...
FDA’s New Dataset Aims To Assist Labs In Assessing Medical Device Biocompatibility
The US FDA’s device center has unveiled a new public dataset designed to assist chemistry laboratories in ensuring the robustness of chemical characterization methods used to assess the biocompatibility of medical devices.
Sanofi Prepares Pulmonologists As Dupixent Nears COPD Finishing Line
The French drugmaker has identified education as a key challenge ahead of its June action date for the huge-selling IL4/IL-13 inhibitor in the lung condition. An approval would make it the first biologic for the disease.
Global Pharma Guidance Tracker – March 2024
Stay up to date on regulatory guidelines from around the world with the Pink Sheet's Guidance Tracker. The complete Global Pharma Guidance Tracker, with sortable and searchable listings going back to 2014, is available online.